Review article
https://doi.org/10.26800/LV-146-supl1-7
Biological therapy in atopic diseases
Iva Mrkić Kobal
orcid.org/0000-0003-4016-4504
*
Mirjana Turkalj
* Corresponding author.
Abstract
Over the past decade, advancements in understanding the pathogenetic mechanisms of allergicdiseases have led to the development of molecularly specific drugs, known as biological drugs, which have proveneffective in treating refractory allergic conditions. Their application has demonstrated efficacy in reducing the severity and frequency of allergic reactions, with an excellent safety profile. The most effective drugs are those that regulate the Th-2 inflammatory response and counteract the effects of Th-2 interleukins (IL): IL-4, IL-5, IL-13, and immunoglobulin E (IgE). In clinical practice, with defined indications, drugs such as omalizumab, mepolizumab, dupilumab, reslizumab, tezepelumab, and others have shown to be excellent alternatives to oral corticosteroid therapy, especially in treating patients with asthma, as well as in other allergic conditions such as food allergies, chronic urticaria, chronic rhinosinusitis with nasal polyposis, and idiopathic anaphylaxis. The choice of a biological drug depends on the endotype of the individual patient’s disease. Due to these developments, the era of biological treatment is considered to have opened a chapter in what is known as a personalized approach to treatment, or precision medicine. The ongoing development of new monoclonal antibodies targeting mediators of the Th-2 inflammatory response increases the potential for success in further advancing biological drug development,
treating allergic diseases, and addressing other conditions associated with this type of inflammation.
Keywords
SEVERE ASTHMA: ATOPIC DERMATITIS; CHRONIC IDIOPATHIC URTICARIA; CHRONIC RHINOSINUSISTIS WITH NASAL POLYPOSIS; FOOD ALLERGY; ANAPHYLAXIS; BIOLOGIC THERAPY
Hrčak ID:
315819
URI
Publication date:
11.4.2024.
Visits: 1.018 *